Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04883138 · ClinicalTrials.gov registry record · Phase 1
Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients
A Phase 1 study, sponsored by GigaGen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04883138: Clinical Trial Phase 1 study, sponsored by GigaGen.
NCT04883138 is a Phase 1 study that was terminated before completion, run by GigaGen. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04883138, a Phase 1 study, was terminated before completion, sponsored by GigaGen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
Primary Outcome
Frequency of TEAEs graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Interventions
- DRUG GIGA-2050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-01-11 |
| Phase | Phase 1 |
Why NCT04883138 stopped before completion
NCT04883138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which GIGA-2050 is the first listed.
NCT04883138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04883138 about?
NCT04883138 is a clinical study titled "Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients". The purpose of this study is to evaluate the safety and tolerability of single ascending IV dose administrations of GIGA-2050 in patients hospitalized with COVID-19.
What is the current status of trial NCT04883138?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-05-24. Estimated completion is 2022-01-11.
What interventions are being tested in trial NCT04883138?
The interventions under investigation include: GIGA-2050 (DRUG).
Who is sponsoring clinical trial NCT04883138?
This trial is sponsored by GigaGen, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04883138's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI